Pratter M R, Bartter T C, Dubois J
Department of Medicine, Robert Wood Johnson School of Medicine, Cooper Hospital/University Medical Center, Camden, NJ.
Chest. 1993 Nov;104(5):1342-5. doi: 10.1378/chest.104.5.1342.
We undertook a prospective study of bronchoprovocation challenge (BPC) to look at issues of safety and reversibility of bronchospasm and symptoms induced by BPC. Over a 14-month interval, we documented 62 consecutive cases of bronchial hyperresponsiveness. During BPC, there was a statistically significant but clinically modest increase in both cough and dyspnea. Both bronchospasm and symptoms were readily reversed with a simple protocol of inhaled albuterol using a metered-dose inhaler with a spacer. Routine protocol was effective in every case; there was never a need for individualized physician intervention. Our prospective data document the safety of BPC; we could find no reason why BPC would need to be confined to the hospital. We conclude that BPC is a valuable clinical test which merits wider dissemination and use.
我们进行了一项支气管激发试验（BPC）的前瞻性研究，以探讨BPC诱发的支气管痉挛的安全性、可逆性以及相关症状。在14个月的时间里，我们记录了连续62例支气管高反应性病例。在BPC期间，咳嗽和呼吸困难均有统计学意义但临床上增幅不大的增加。使用带储雾罐的定量吸入器吸入沙丁胺醇的简单方案能使支气管痉挛和症状迅速逆转。常规方案在每个病例中均有效；从未需要医生进行个体化干预。我们的前瞻性数据证明了BPC的安全性；我们找不到BPC需要局限于医院进行的理由。我们得出结论，BPC是一项有价值的临床检查，值得更广泛地推广和应用。
